Altamira Therapeutics (CYTO)
(Delayed Data from NSDQ)
$0.66 USD
+0.05 (8.08%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $0.60 -0.06 (-8.99%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CYTO 0.66 +0.05(8.08%)
Will CYTO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CYTO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CYTO
Altamira Therapeutics Faces Nasdaq Delisting
Altamira Therapeutics receives Nasdaq non-compliance letter
Altamira Therapeutics provides update on Nasdaq listing
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Altamira obtains extended ISO 13485 quality management system certification